Compare Novavax Inc (NVAX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs TeraWulf Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while TeraWulf Inc trades at $13.77 (market cap $6.81B). The key difference: TeraWulf Inc is far larger — about 3.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and TeraWulf Inc for 17 Days on average.
| NVAX | WULF | |
|---|---|---|
Market Cap | $1.82B | $6.81B |
Volume | 6,198,505 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $12.75 | $28.98 |
52-Week Low | $6.22 | $10.99 |
Typical Hold Time | 59 Days | 17 Days |
Enterprise Value | $1.39B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
WULF trades at $13.65, down 5.21% today, amid a bearish technical signal and weak fundamentals. The company reported a net loss of -$661.42M on $168.46M revenue in 2025, with negative margins and high valuation ratios. Recent news highlights volatility tied to AI infrastructure trends, with shares reacting to sector momentum. Cash flow remains positive from financing, but operational and investing cash flows are negative, indicating heavy capital expenditure.
Outlook is mixed: analyst consensus is strongly bullish with a $34.92 price target, but high losses and bearish technicals pose risks. Investment opportunity hinges on successful AI data center pivot, while risks include persistent unprofitability, competitive pressures, and reliance on financing. Investors should weigh growth potential against financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
